These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 33941587)

  • 1. T Cells Expressing Receptor Recombination/Revision Machinery Are Detected in the Tumor Microenvironment and Expanded in Genomically Over-unstable Models.
    Morello G; Cancila V; La Rosa M; Germano G; Lecis D; Amodio V; Zanardi F; Iannelli F; Greco D; La Paglia L; Fiannaca A; Urso AM; Graziano G; Ferrari F; Pupa SM; Sangaletti S; Chiodoni C; Pruneri G; Bardelli A; Colombo MP; Tripodo C
    Cancer Immunol Res; 2021 Jul; 9(7):825-837. PubMed ID: 33941587
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T cell receptor repertoires of ex vivo-expanded tumor-infiltrating lymphocytes from breast cancer patients.
    Park IA; Rajaei H; Kim YA; Lee H; Lee H; Seo JH; Heo SH; Song IH; Gong G; Lee HJ
    Immunol Res; 2020 Oct; 68(5):233-245. PubMed ID: 32886262
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multispectral quantitative immunohistochemical analysis of tumor-infiltrating lymphocytes in relation to programmed death-ligand 1 expression in triple-negative breast cancer.
    Sugie T; Sato E; Miyashita M; Yamaguchi R; Sakatani T; Kozuka Y; Moritani S; Suzuki E; Kakimi K; Mikami Y; Moriya T
    Breast Cancer; 2020 Jul; 27(4):519-526. PubMed ID: 32447649
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune microenvironment in ductal carcinoma in situ: a comparison with invasive carcinoma of the breast.
    Kim M; Chung YR; Kim HJ; Woo JW; Ahn S; Park SY
    Breast Cancer Res; 2020 Mar; 22(1):32. PubMed ID: 32216826
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Relationship between T cell receptor clonotype and PD-1 expression of tumor-infiltrating lymphocytes in colorectal cancer.
    Sukegawa K; Shitaoka K; Hamana H; Kobayashi E; Miyahara Y; Fujii K; Tsuda K; Saeki S; Nagata T; Ozawa T; Saito S; Fujii T; Muraguchi A; Shiku H; Kishi H
    Eur J Immunol; 2020 Oct; 50(10):1580-1590. PubMed ID: 32441316
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
    Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
    J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Differential Expression of CD49a and CD49b Determines Localization and Function of Tumor-Infiltrating CD8
    Melssen MM; Lindsay RS; Stasiak K; Rodriguez AB; Briegel AM; Cyranowski S; Rutkowski MR; Conaway MR; Melief CJM; van der Burg SH; Eyo U; Slingluff CL; Engelhard VH
    Cancer Immunol Res; 2021 May; 9(5):583-597. PubMed ID: 33619119
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differences in TCR repertoire and T cell activation underlie the divergent outcomes of antitumor immune responses in tumor-eradicating versus tumor-progressing hosts.
    Woolaver RA; Wang X; Krinsky AL; Waschke BC; Chen SMY; Popolizio V; Nicklawsky AG; Gao D; Chen Z; Jimeno A; Wang XJ; Wang JH
    J Immunother Cancer; 2021 Jan; 9(1):. PubMed ID: 33414263
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tumor-infiltrating regulatory T cells, CD8/Treg ratio, and cancer stem cells are correlated with lymph node metastasis in patients with early breast cancer.
    Solis-Castillo LA; Garcia-Romo GS; Diaz-Rodriguez A; Reyes-Hernandez D; Tellez-Rivera E; Rosales-Garcia VH; Mendez-Cruz AR; Jimenez-Flores JR; Villafana-Vazquez VH; Pedroza-Gonzalez A
    Breast Cancer; 2020 Sep; 27(5):837-849. PubMed ID: 32180141
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Transcriptional programs of neoantigen-specific TIL in anti-PD-1-treated lung cancers.
    Caushi JX; Zhang J; Ji Z; Vaghasia A; Zhang B; Hsiue EH; Mog BJ; Hou W; Justesen S; Blosser R; Tam A; Anagnostou V; Cottrell TR; Guo H; Chan HY; Singh D; Thapa S; Dykema AG; Burman P; Choudhury B; Aparicio L; Cheung LS; Lanis M; Belcaid Z; El Asmar M; Illei PB; Wang R; Meyers J; Schuebel K; Gupta A; Skaist A; Wheelan S; Naidoo J; Marrone KA; Brock M; Ha J; Bush EL; Park BJ; Bott M; Jones DR; Reuss JE; Velculescu VE; Chaft JE; Kinzler KW; Zhou S; Vogelstein B; Taube JM; Hellmann MD; Brahmer JR; Merghoub T; Forde PM; Yegnasubramanian S; Ji H; Pardoll DM; Smith KN
    Nature; 2021 Aug; 596(7870):126-132. PubMed ID: 34290408
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review of the Tumor-Infiltrating CD8
    Shadbad MA; Asadzadeh Z; Hosseinkhani N; Derakhshani A; Alizadeh N; Brunetti O; Silvestris N; Baradaran B
    Front Immunol; 2021; 12():734956. PubMed ID: 34603316
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteogenomic identification of an immunogenic HLA class I neoantigen in mismatch repair-deficient colorectal cancer tissue.
    Hirama T; Tokita S; Nakatsugawa M; Murata K; Nannya Y; Matsuo K; Inoko H; Hirohashi Y; Hashimoto S; Ogawa S; Takemasa I; Sato N; Hata F; Kanaseki T; Torigoe T
    JCI Insight; 2021 Jul; 6(14):. PubMed ID: 34185709
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mouse PVRIG Has CD8
    Murter B; Pan X; Ophir E; Alteber Z; Azulay M; Sen R; Levy O; Dassa L; Vaknin I; Fridman-Kfir T; Salomon R; Ravet A; Tam A; Levin D; Vaknin Y; Tatirovsky E; Machlenkin A; Pardoll D; Ganguly S
    Cancer Immunol Res; 2019 Feb; 7(2):244-256. PubMed ID: 30659055
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Checkpoint blockade immunotherapy enhances the frequency and effector function of murine tumor-infiltrating T cells but does not alter TCRβ diversity.
    Kuehm LM; Wolf K; Zahour J; DiPaolo RJ; Teague RM
    Cancer Immunol Immunother; 2019 Jul; 68(7):1095-1106. PubMed ID: 31104075
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CD39 Expression Defines Cell Exhaustion in Tumor-Infiltrating CD8
    Canale FP; Ramello MC; Núñez N; Araujo Furlan CL; Bossio SN; Gorosito Serrán M; Tosello Boari J; Del Castillo A; Ledesma M; Sedlik C; Piaggio E; Gruppi A; Acosta Rodríguez EA; Montes CL
    Cancer Res; 2018 Jan; 78(1):115-128. PubMed ID: 29066514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. scRNA+ TCR-seq revealed dual TCR T cells antitumor response in the TME of NSCLC.
    Peng Q; Xu Y; Yao X
    J Immunother Cancer; 2024 Sep; 12(9):. PubMed ID: 39237261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Low mutation and neoantigen burden and fewer effector tumor infiltrating lymphocytes correlate with breast cancer metastasization to lymph nodes.
    Wang Z; Liu W; Chen C; Yang X; Luo Y; Zhang B
    Sci Rep; 2019 Jan; 9(1):253. PubMed ID: 30670769
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NFATc1 Promotes Antitumoral Effector Functions and Memory CD8
    Heim L; Friedrich J; Engelhardt M; Trufa DI; Geppert CI; Rieker RJ; Sirbu H; Finotto S
    Cancer Res; 2018 Jul; 78(13):3619-3633. PubMed ID: 29691251
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The number of FoxP3-positive tumor-infiltrating lymphocytes in patients with synchronous bilateral breast cancer.
    Goto R; Hirota Y; Aruga T; Horiguchi S; Miura S; Nakamura S; Takimoto M
    Breast Cancer; 2020 Jul; 27(4):586-593. PubMed ID: 31933123
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Radiotherapy and CTLA-4 Blockade Shape the TCR Repertoire of Tumor-Infiltrating T Cells.
    Rudqvist NP; Pilones KA; Lhuillier C; Wennerberg E; Sidhom JW; Emerson RO; Robins HS; Schneck J; Formenti SC; Demaria S
    Cancer Immunol Res; 2018 Feb; 6(2):139-150. PubMed ID: 29180535
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.